UNITED KINGDOM — AstraZeneca has made headlines by agreeing to acquire Seattle-based biotech firm Icosavax for a substantial sum of up to US$1.1 billion.
The deal encompasses the addition of Icosavax’s investigational respiratory syncytial virus (RSV) vaccine candidate, IVX-A12, to AstraZeneca’s already extensive vaccine pipeline.
This comes as AstraZeneca seeks to reinforce its position in the rapidly evolving landscape of preventive medicine.
Under the terms of the agreement, AstraZeneca will pay US$800 million in upfront cash for Icosavax. The deal’s overall value, calculated at US$15 per share, represents a considerable 43% premium on Icosavax’s share price at the close of the market on the preceding day.
Additionally, Icosavax’s shareholders stand to receive an extra US$5 in cash per share if specific regulatory and sales milestones are achieved.
At the heart of this transformative acquisition is Icosavax’s Phase III-ready protein virus-like particle (VLP) vaccine, IVX-A12, designed to target both RSV and human metapneumovirus (hMPV).
The strategic move coincides with Icosavax’s release of interim data from a Phase 2 trial involving 264 healthy adults aged 60-85 years.
The trial demonstrated that IVX-A12 induced robust immune responses to both RSV and hMPV after 28 days, irrespective of whether administered alone or in combination with CSL Seqirus’ adjuvant MF59.
Importantly, the trial reaffirmed the safety data observed in Phase 1, with no vaccine-related serious adverse events reported during the Phase 2 trial.
IVX-A12 is positioned by AstraZeneca as “the most advanced investigational vaccine targeting both RSV and hMPV.”
The company highlights its “differentiated profile versus currently approved RSV vaccines,” indicating a belief in the unique qualities that set IVX-A12 apart.
Virus-like particle (VLP) vaccines, such as IVX-A12, mimic the appearance of naturally occurring viruses to the body’s immune system.
AstraZeneca is optimistic that this innovative technology will provide IVX-A12 with advantages in terms of immune response, durability, and fewer side effects compared to existing approved options.
Iskra Reic, AstraZeneca’s EVP of vaccines and immune therapies, expressed enthusiasm for the transformative potential of IVX-A12, stating, “This virus-like particle vaccine technology has the potential to transform prevention against severe infectious diseases, including RSV and hMPV.”
With the addition of Icosavax’s Phase III-ready lead asset to AstraZeneca’s late-stage pipeline, the company positions itself to develop advanced investigational vaccines and pursue further combinations targeting respiratory viruses.
This move comes at a time when the pharmaceutical giant is navigating the complex landscape of vaccine development, having brought one of the world’s most widely used COVID-19 shots to market in recent years.
The acquisition aligns with AstraZeneca’s overarching strategy to deliver a comprehensive portfolio of therapies that address high unmet needs in infectious diseases.
This strategic leap into the RSV vaccine market is part of a broader industry trend, with analysts estimating the potential opportunity to exceed US$10 billion.
AstraZeneca is not alone in recognizing the significance of this market, as other major players like Pfizer and GSK have made strides in adult RSV vaccine development.